Suppr超能文献

相似文献

1
PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease.
Cell Metab. 2021 Jun 1;33(6):1187-1204.e9. doi: 10.1016/j.cmet.2021.04.018. Epub 2021 May 17.
2
Nonalcoholic fatty liver disease and gastric bypass surgery regulate serum and hepatic levels of pyruvate kinase isoenzyme M2.
Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E613-E621. doi: 10.1152/ajpendo.00296.2017. Epub 2018 Feb 20.
3
CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy.
J Hepatol. 2016 Jan;64(1):160-70. doi: 10.1016/j.jhep.2015.09.005. Epub 2015 Sep 21.
4
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
Clin Exp Immunol. 2011 Nov;166(2):281-90. doi: 10.1111/j.1365-2249.2011.04471.x.
6
Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis.
PLoS One. 2016 Feb 19;11(2):e0149783. doi: 10.1371/journal.pone.0149783. eCollection 2016.
8
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
World J Gastroenterol. 2016 Nov 7;22(41):9096-9103. doi: 10.3748/wjg.v22.i41.9096.
9
Research progress on the role of PKM2 in the immune response.
Front Immunol. 2022 Jul 28;13:936967. doi: 10.3389/fimmu.2022.936967. eCollection 2022.
10
PKM2-dependent glycolysis promotes NLRP3 and AIM2 inflammasome activation.
Nat Commun. 2016 Oct 25;7:13280. doi: 10.1038/ncomms13280.

引用本文的文献

2
Innate Immunity Reimagined: Metabolic Reprogramming as a Gateway to Novel Therapeutics.
Int J Biol Sci. 2025 Jul 28;21(11):5056-5078. doi: 10.7150/ijbs.114010. eCollection 2025.
4
Inflammation in MASLD progression and cancer.
JHEP Rep. 2025 Apr 2;7(8):101414. doi: 10.1016/j.jhepr.2025.101414. eCollection 2025 Aug.
5
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD.
Immunotargets Ther. 2025 Jul 11;14:719-733. doi: 10.2147/ITT.S530451. eCollection 2025.
6
CD4 T cells promote fibrosis during metabolic dysfunction-associated steatohepatitis.
bioRxiv. 2025 Jul 3:2025.06.27.660220. doi: 10.1101/2025.06.27.660220.
7
Immunopathogenic mechanisms and immunoregulatory therapies in MASLD.
Cell Mol Immunol. 2025 Jun 10. doi: 10.1038/s41423-025-01307-5.
8
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC.
Front Immunol. 2025 Apr 30;16:1569915. doi: 10.3389/fimmu.2025.1569915. eCollection 2025.
9
Macrophage PKM2 depletion ameliorates hepatic inflammation and acute liver injury in mice.
Front Pharmacol. 2025 Apr 25;16:1546045. doi: 10.3389/fphar.2025.1546045. eCollection 2025.
10
Defective autophagy in CD4 T cells drives liver fibrosis via type 3 inflammation.
Nat Commun. 2025 Apr 24;16(1):3860. doi: 10.1038/s41467-025-59218-y.

本文引用的文献

1
Modulation of PKM activity affects the differentiation of T17 cells.
Sci Signal. 2020 Oct 27;13(655):eaay9217. doi: 10.1126/scisignal.aay9217.
2
Contrasting contributions of TNF from distinct cellular sources in arthritis.
Ann Rheum Dis. 2020 Nov;79(11):1453-1459. doi: 10.1136/annrheumdis-2019-216068. Epub 2020 Aug 12.
3
Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis.
Immunity. 2020 Jun 16;52(6):1057-1074.e7. doi: 10.1016/j.immuni.2020.04.001. Epub 2020 May 1.
4
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
Sci Transl Med. 2019 Nov 27;11(520). doi: 10.1126/scitranslmed.aav9701.
5
Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4 T Cell Pathogenicity and Suppresses Autoimmunity.
Cell Metab. 2020 Feb 4;31(2):391-405.e8. doi: 10.1016/j.cmet.2019.10.015. Epub 2019 Nov 21.
6
Resolving the fibrotic niche of human liver cirrhosis at single-cell level.
Nature. 2019 Nov;575(7783):512-518. doi: 10.1038/s41586-019-1631-3. Epub 2019 Oct 9.
8
cellHarmony: cell-level matching and holistic comparison of single-cell transcriptomes.
Nucleic Acids Res. 2019 Dec 2;47(21):e138. doi: 10.1093/nar/gkz789.
9
Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation.
Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1;317(4):G387-G397. doi: 10.1152/ajpgi.00054.2019. Epub 2019 Aug 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验